en

PRODUCT DETAIL

KANJINTI 150 mg prášok na infúzny koncentrát

Code 7943C
MA number EU/1/18/1281/001
Product Form: plc ifc 1x150 mg (liek.inj.skl.)
MA Status: E - Valid centralised marketing authorisation
Type of procedure: EU
MAH, country: Amgen Europe B.V., Netherland
Therapeutic Class: 44 - CYTOSTATICA
ATC:
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
L01FD HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
L01FD01 Trastuzumab
Shelf life: 36
Container: glass vial
Route of admin.: Intravenous use
Prescription Status: Medicinal product subject to restricted medical prescription.
Legal basis: Article 10(4) similar biological application
MA issued: 16.05.2018
SmPC + PL: European Medicines Agency's database
Safety feature Yes
Data update: 09.02.2023
eu-flag.png sk-flag.png